Results 61 to 70 of about 129 (87)

Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer

Marine Drugs, 2015
Protein phosphatase 2A (PP2A) is a tumor suppressor complex that has recently been reported as a novel and highly relevant molecular target in prostate cancer (PCa). However, its potential therapeutic value remains to be fully clarified.
Ion Cristóbal, Paula González-Alonso, Lina Daoud, Esther Solano, Blanca Torrejón, Rebeca Manso, Juan Madoz-Gúrpide, Federico Rojo, Jesús García-Foncillas   +8 more
doaj   +1 more source

Penfluridol inhibits melanoma growth and metastasis through enhancing von Hippel‒Lindau tumor suppressor‐mediated cancerous inhibitor of protein phosphatase 2A (CIP2A) degradation

MedComm
Melanoma's high metastatic potential, especially to the brain, poses significant challenges to patient survival. The blood‒brain barrier (BBB) is a major obstacle to the effective treatment of melanoma brain metastases.
Fuyan Xu, Jiao Li, Min Ai, Tingting Zhang, Yue Ming, Cong Li, Wenchen Pu, Yang Yang, Zhang Li, Yucheng Qi, Xiaomin Xu, Qingxiang Sun, Zhu Yuan, Yong Xia, Yong Peng   +14 more
doaj   +1 more source

Pharmacological Reactivation of PP2A by SET/CIP2A Inhibition Attenuates Triple Negative Breast Cancer Progression

Kinases and Phosphatases
The tumor suppressor protein phosphatase 2A (PP2A) plays a crucial role in regulating oncogenic signaling. Its inactivation, specifically through inhibitory phosphorylation at Tyr307 mediated by SET and CIP2A, contributes to breast cancer (BC ...
Gustavo Adolfo Barraza, Joselina Magali Mondaca, Juan Manuel Fernandez Muñoz, Bruno Mariano Vinante, Marina Inés Flamini, Angel Matias Sanchez   +5 more
doaj   +1 more source

Abstracts

Molecular Oncology, Volume 19, Issue S1, Page 1-940, June 2025.
Abstracts submitted to the ‘EACR 2025 Congress: Innovative Cancer Science’, from 16–19 June 2025 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Resveratrol Mimics Exercise-Induced Metabolic Stress to Suppress CIP2A and Epithelial–Mesenchymal Transition in 3D Renal Carcinoma Spheroids

Biomedicines
Background/Objectives: We evaluated a 6-day repeated resveratrol exposure regimen in a three-dimensional (3D) culture model of human renal cell carcinoma (Caki-1) spheroids to examine phenotypic responses and changes in CIP2A abundance and epithelial ...
Bang Sub Lee, Jong-Shik Kim, Wi-Young So
doaj   +1 more source

The CIP2A-TOPBP1 axis facilitates mitotic DNA repair via MiDAS and MMEJ

Nature Communications
Mitotic DNA double-strand breaks (DSBs) accumulate in response to replication stress or BRCA1/2 deficiency posing a significant threat to genome stability as repair by non-homologous end-joining (NHEJ) and homologous recombination (HR) is largely ...
Peter R. Martin, Jadwiga Nieminuszczy, Zuza Kozik, Nihal Jakub, Szymon Kowalski, Maxime Lecot, Julia Vorhauser, Karen A. Lane, Alexandra Kanellou, Jörg Mansfeld, Laurence H. Pearl, Antony W. Oliver, Jessica A. Downs, Jyoti S. Choudhary, Matthew Day, Wojciech Niedzwiedz   +15 more
doaj   +1 more source

靶向CIP2A的shRNA对人肠癌细胞生物学特征的影响

Zhongshan Daxue xuebao. Yixue kexue ban, 2018
【目的】探讨shRNA介导的CIP2A基因表达对肠癌HT29细胞生物学特性的影响。【方法】采用RTPCR及Westernblot检测重组质粒转染肠癌HT29细胞前后mRNA和蛋白的变化；分别采用CCK8、Transwell小室 法、流式细胞术及裸鼠成瘤实验（n＝20）测定其对肠癌HT29细胞增殖、克隆形成、凋亡及侵袭能力的影响。【结 果】shRNA-CIP2A转染肠癌HT29细胞后，肠癌HT29细胞内CIP2AmRNA和蛋白的表达明显下降。实验组肠癌 HT29细胞增殖明显受到抑制 ...
梁景琳, 叶俊文, 汪建平, 黄美近   +3 more
doaj  

DP133 | CIP2A IS IMPLICATED IN RUXOLITINIB RESISTANCE IN MYELOFIBROSIS

Haematologica
Although ruxolitinib (Ruxo) is the standard of care for patients (pts) with myelofibrosis (MF), therapeutic resistance develops in approximately 50% within 3-5 years, posing a clinical challenge.
M. Balliu, M. Vannucchi, M.C. Siciliano, M. Lomi, C. Basile, P. Guglielmelli, A.M. Vannucchi   +6 more
doaj  

Some of the next articles are maybe not open access.

Related searches:

Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia

Cancers, 2021
Claire M Lucas, Jane F Apperley
exaly  

The Role of CIP2A in Cancer: A Review and Update

Biomedicine and Pharmacotherapy, 2017
Mohammad Saeid Hejazi, Behzad Baradaran
exaly